Mar 23, 2022
-- Apraglutide, a next-generation GLP-2 analog, protected against chemotherapy-induced gastrointestinal (GI) damage and improved survival in mouse models of GI acute graft-versus-host disease (aGVHD) -- -- Data support regenerative, non-immunosuppressive hypothesis for clinical evaluation; launched ...
Feb 08, 2022
BASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive ...
Copyright © VectivBio AG, 2022. All Rights Reserved.